IL6 and metabolic syndrome: According to the hypothesis that inflammation causes dyslipidemia in RA patients, the finding of this study can disclose the possible impact of IL‐6, as an important inflammatory agent, in dyslipidemia and increase the risk of CVD in RA patients.45, 48